SELENON and central nervous system cancer: The TCGA-LGG, CGGA-693, CGGA-325, GSE16011, and ZN-GC cohorts all confirmed that high SEPN1 expression was associated with shorter OS in glioma patients, establishing it as an independent prognostic risk factor.